Feel, I admit I don't know what I am talking about but is this same space as Car-t drugs that outfits like kite and Juno looking at. Those folks have multibillion dollar caps. People enamored with immunotherapy, this seems like better shot..
Blph went public on Friday and got a pretty weak reception. Why am I mentioning this because they are blrx's partner on 1040 our cardiac gel. Not a ringing endorsement of blph by the street. Hopefully not an indication of our product.
They went out at 12 and preceded to lose 25%.
There are 14k shares short a real coverage problem.
Thought that it is interesting that they are having the ash meeting and then a follow up a week or so later with investment community. Maybe they think they have something.
Do you Realize that the enterprise value is 14 mil. That is virtually saying the company is worth nothing. Doesn't seem to be that bad to me. They have stuff in clinical trials must be worth something.
understand we have to start somewhere, but with no data on efficacy it is hard to know if we have anything. On the other hand if it works.....there is pretty darn big market out there and as of yet no competition. would be a good stock to own.
Understand your concern. Had pretty decent numbers and an upbeat call. Subtract the $6 bucks in cash and your talking a pretty low pe on non gaap numbers. Even based on gaap not that bad.
From questions on call maybe want better margins. This should work out eventually. Probably buy out. Well at least I hope it works out.
I figured as long as the company released fourth quarter results and went through the trouble of putting together a presentation it should be acknowledged.
No real hot news but it is a good way to get an understanding of the pipeline and the important milestones this year.
look and listen, it is on the company website under investors.
Looks like we have a lot of shares to burn off before can move higher. That is OK since we have a second half stock here anyway. Might as well base here.
No flames, I have a decent position that I am adding to. Seems very cheap to me, but it all depends on execution. Could be a very good year for us. Assuming maket half way decent we will be higher in time.
Good Luck and Peace
Had to do this, don't love price but could be a wonderful entry point. Now up to management to produce. This is a second half of year stock, some good news will double us up, let's hope we get it.
If you do a google search using pharmatelevision David Malek Bioline you should find an interview that was published February 21. I think it is pretty good and worth listening to.
I guess there could be a large seller out there but we don't seem to get any traction here. I guess an investor could look at this as a good time to compile shares. Seems to me only one of our items has to do well for the company value to rise and if we got some good news on multiple items at the end of the year we should do great. I am anxious for year end report and to find out if blrx is the seller.
Listened to todays investor conference. Looks like we have to wait until the fourth quarter for the real catalysts to come to the for. I still think cash is an issue and will not invest more until they do some kind of dilution or stock drops for some other reason, but that is just me. Otherwise this is cheap. One of our items will get good news and really propel us.
Don't disagree I would love to see shorts burn. I think the issue here is cash. Blrx needs cash (I know they have enough to 2015 but this is already 2014) so my guess is the shorts are banking on a secondary. Either we will have a cash deal in next six months or we will have to dilute. My money is on the former or I would not be invested. Toxic is right was not a bad deal for us it distributed our costs but we still need cash.
I believe it is the second half of 2014. If you go to the company website, go to investors and the December 23 presentation. On slide 34 you will see a graphic on key dates for 2014. Looks like 1040 in second half.
I am surprised we are not getting greater love. Our results on 8040 were very early stage and realistically starting a phase one study may not be a stock driver however; the portfolio is a nice one and the news is good. Later in 2014 we have a good chance to go significantly higher as we will get later stage results on a number of products. Very hopeful we could have a very nice upside.
This is excellent news, the company going into today only had a valuation of sixty million, with several very good opportunities in 2014 we have the making of a real winner. Very exciting indeed.
Having had a small position in iMuc, which had bad phase 2 data, down 50% I hear your pain. I also own quite a bit of cgen so am having a miserable day. I hope we don't strike out here it will be their second major disappointment. I m looking for the second half of 2014 to have some positives, I just don't need another sinker. Good luck to all.
Would like to get excited about todays announcement but there is really nothing new here. it is preclinical information, the type that one would expect if drug is taken into clinicals. They say info before year end so should be follow up information any day now.
That is absolutely correct; however, we are a couple of weeks from 2014, realistically blrx can't wait until 2015 to raise money, they will have to get some before then. That could come from a licensing deal or sale of shares. If a sale is necessary we would want it to be after some good news so dilution would be minimal, if we wait to long without confidence by the investor community it will coast us in dilution. News good or bad should be out fairly soon.